Healthcare, Pharma & Life Sciences

Innovent to Unveil Phase 3 Gastric Cancer ADC Data at ESMO 2026

Suzhou, China – September 24, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

Phase 3 gastric cancer trial secures late-breaking oral slot

Results from the registrational G-HOPE-001 study, comparing Arcotatug Tavetecan against treatment of physician's choice in previously treated advanced gastric or gastroesophageal junction adenocarcinoma, will be delivered as a late-breaking abstract (LBA77) during the October 23 proffered paper session. Dr. Kohei Shitara of Chiba, Japan, will present the first interim analysis of the randomized, open-label trial.

Sharps Assure Named Top Mail-Back Waste Provider for Dental Offices

New York – – September 24, 2026 -- Better Business Advice has named Sharps Assure a top mail-back medical waste provider for dental offices, citing its sharps container range, dental amalgam disposal product, and prepaid return services.

Sharps Assure offers five container sizes to match variable dental waste volumes

The company provides 1-quart, 1.5-quart, 1-gallon, 2-gallon, and larger-capacity sharps systems, allowing practices to size disposal capacity to procedure volume rather than committing to fixed collection schedules typical of larger healthcare facilities.

Dent Assure Waste Amalgam gives dental offices a dedicated stream for restorative waste

Amalgam waste generated during fillings, removals, or equipment maintenance requires separate handling from standard sharps. Sharps Assure's dedicated product lets practices route this material away from ordinary sharps or office waste streams.

Caliway's CBL-514 Meets Primary Endpoint in Dercum's Disease Trial

Image
Caliway's CBL-514 Meets Primary Endpoint in Dercum's Disease Trial

New Taipei City – September 24, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) said on September 21 that its Phase 2 CBL-0202DD trial of CBL-514 met its primary efficacy endpoint, delivering statistically significant pain reduction in patients with Dercum's Disease compared with placebo, in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations.

CBL-514 Cuts Pain Scores by 3.1 Points at Week 20 Versus Placebo

In the FAS population, patients treated with CBL-514 achieved a mean pain-score reduction of 3.1 points at Week 20, versus 1.9 points for placebo (p=0.005). In the PP population, the same 3.1-point reduction was measured against a 1.4-point placebo response (p=0.0002).

eHealth, BerniePortal Partner to Expand CHOICE Health Plan Access

Image
eHealth, BerniePortal Partner to Expand CHOICE Health Plan Access

Indianapolis – September 23, 2026 -- eHealth, Inc. (Nasdaq: EHTH) has partnered with benefits administration platform BerniePortal to connect more than 5,000 employers and over 1,000 insurance brokers to individual health coverage options under the newly renamed Custom Health Option and Individual Care Expense Arrangements, or CHOICE.

CMS renamed ICHRA to CHOICE arrangements as of September 3, 2026

The Centers for Medicare and Medicaid Services officially rebranded Individual Coverage Health Reimbursement Arrangements as CHOICE arrangements earlier this month, a shift now embedded in the eHealth-BerniePortal distribution model. Under CHOICE, employers provide employees a defined contribution toward individual health coverage rather than a traditional group plan, shifting cost predictability and plan selection to the employee level.

Eskenazi Joins Faculty of 14th Annual IAFA Aesthetic Symposium

Image
Eskenazi Joins Faculty of 14th Annual IAFA Aesthetic Symposium

Miami Beach, Fla. – September 23, 2026 -- Benjamin Eskenazi MD, FACS, founder of Avabello Aesthetics, has been named to the faculty of the 14th Annual IAFA Aesthetic Symposium, set for the Fontainebleau Miami Beach on November 6-7, 2026.

Dr. Eskenazi will co-instruct a pre-symposium injection masterclass on November 5

The five-hour Anatomy & Injection Masterclass runs from 2:00 to 7:00 p.m. and is led by Professor Sebastian Cotofana, MD, PhD, PhD. The course combines cadaver dissections with live patient injection demonstrations and real-time facial ultrasound, covering neurotoxin treatment of the forehead, glabella and crow's feet, and filler treatment of the temples, tear troughs, cheeks, nasolabial folds, lips, chin and jawline. Dr. Eskenazi will perform live injections alongside co-instructors Terry Alford, DMD; Lanna Cheuck, DO; Barbara Brandt, APRN; Jill Campbell, MSN, FNP-C, CANS; and Shanna Concepcion, RN, CANS.

Mölnlycke Report Finds Hospitals Underuse Day Surgery Capacity

Gothenburg – September 23, 2026 -- Mölnlycke Health Care has released The Hidden Capacity Report, an international study identifying significant untapped capacity in day surgery that could improve surgical throughput and reduce waiting times across healthcare systems.

Survey of 256 healthcare professionals across ten countries exposes adoption gaps

The report draws on a review of international literature, a survey of 256 healthcare professionals across ten countries, expert interviews and guidance from an international expert panel of key opinion leaders. Despite strong clinical evidence supporting day surgery, adoption remains inconsistent across countries, healthcare organisations, specialties and individual clinical teams.

GROWNSY Debuts at NANN Conference, Partners on Nasal Congestion Podcast

Image
GROWNSY Debuts at NANN Conference, Partners on Nasal Congestion Podcast

West Palm Beach – September 23, 2026 -- GROWNSY, a baby care brand serving over 3 million households globally, exhibited for the first time at NANN's 42nd Annual Conference held September 15-18, 2026, in West Palm Beach, Florida, marking its entry into the neonatal clinical channel.

GROWNSY showcases NICU-to-home product line at neonatal nursing conference

The company displayed its SniffEase nasal care line alongside a Compact Bottle Sterilizer and Dryer, Electronic Infant Scale with Height Measurement, Postpartum Recovery Kit, and Perineal Massage and Pelvic Floor Wand, targeting families transitioning from NICU care to home routines.

GROWNSY CEO cites nurse engagement as strategic priority

Yvonne, CEO of GROWNSY, said meeting neonatal nurses who guide families from NICU to home reinforced the company's product development rationale.

Exosomes Market to Hit $2.25B by 2034 on 28.8% CAGR

Image
Exosomes Market to Hit $2.25B by 2034 on 28.8% CAGR

Pune, India – – September 23, 2026 -- The global exosomes market is set to grow nearly tenfold over the next decade, expanding from USD 230.55 million in 2025 to USD 2,250 million by 2034, according to a new analysis from Maximize Market Research. The projected 28.8% compound annual growth rate between 2026 and 2034 places exosome technology among the fastest-expanding segments in biopharmaceutical R&D.

Drug delivery pipelines drive commercial momentum

Pharmaceutical and biotechnology companies are expanding exosome-related pipelines as the nanosized extracellular vesicles gain traction as targeted carriers for drugs, proteins, and RNA. Rising investment in biotechnology and advances in isolation, characterization, and engineering technologies are pushing exosomes beyond research settings into drug development and regenerative medicine applications.

WesternU Hosts Second A.P. Howells Lectureship, Launches New Honors

Image
WesternU Hosts Second A.P. Howells Lectureship, Launches New Honors

Lebanon, Ore. – September 23, 2026 -- Western University of Health Sciences Heatherington College of Osteopathic Medicine (WesternU HCOM) hosted its second annual A.P. Howells, DO, Endowed Lectureship on Aug. 29-30, 2026, training physicians in the Fascial Distortion Model (FDM) for musculoskeletal treatment.

Todd Capistrant, DO, led hands-on FDM training combining online modules with supervised clinical practice

Capistrant, a Medical Director at Foundation Health Partners since 2013 and a board-certified family medicine physician, taught participants to identify fascial distortion patterns and apply introductory osteopathic manipulative treatment techniques. He emphasized that patient activity levels remain a stronger predictor of long-term health outcomes than pharmaceutical interventions for reducing heart disease, stroke, dementia and cancer risk.

OxiWear Signs Exclusive Qatar Distribution Deal with AMNM

Image
OxiWear Signs Exclusive Qatar Distribution Deal with AMNM

Doha – September 23, 2026 -- OxiWear Inc. has signed an exclusive distribution partnership with Alfardan Medical with Northwestern Medicine (AMNM) to bring its wearable physiological measurement technology into Qatar, marking the U.S. company's latest push into the Middle East.

OxiWear taps AMNM's local network to enter Qatar's healthcare technology market

Under the agreement, OxiWear and AMNM will jointly handle distribution, market development, and customer engagement for OxiWear's continuous physiological measurement products across Qatar. AMNM, a multi-specialty day-care surgery center based in Lusail and operated in affiliation with Chicago-based Northwestern Medicine, provides OxiWear with an established clinical network and regional expertise in outpatient care.